TOKAI Full Year 2025 Earnings: Revenues Beat Expectations, EPS Lags

TOKAI (TSE:9729) Full Year 2025 Results

Key Financial Results

• Revenue: JP¥149.5b (up 8.2% from FY 2024).
• Net income: JP¥4.73b (down 19% from FY 2024).
• Profit margin: 3.2% (down from 4.2% in FY 2024). The decrease in margin was driven by higher expenses.
• EPS: JP¥139 (down from JP¥165 in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

TOKAI Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Japan.

Performance of the Japanese Healthcare industry.

The company's shares are up 3.9% from a week ago.

Risk Analysis

Be aware that TOKAI is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.